The 2026 EASO update expands tirzepatide eligibility by 35% and adds new heart‑risk roles for semaglutide. Find out which GLP‑1 drug fits your patients best and why it matters for weight‑loss outcomes.
miriam096
Posted on • Originally published at nexusbase.site
Unlock Weight Secrets Tirzepatide or Semaglutide?
For further actions, you may consider blocking this person and/or reporting abuse
Top comments (0)